Therapeutic Oligonucleotide Services

We support multiple therapeutic oligonucleotide categories including siRNA, antisense oligonucleotides (ASO), aptamers, splice-switching oligonucleotides (SSO), miRNA mimics, and therapeutic oligo bioconjugation strategies.

The correct modality depends on the intended biological mechanism, such as RNA knockdown, splice redirection, pathway modulation, or target binding. This overview page helps users identify the most relevant service area before moving into the detailed technical page.

Yes. Therapeutic oligo programs often require backbone, sugar, end-group, or conjugation-based modifications depending on stability, delivery, and performance goals.

These services are relevant across research, translational, and preclinical workflows. Program scope can range from discovery-stage screening to more structured development support depending on the oligonucleotide class.

Yes. Depending on the modality, therapeutic oligos may be paired with ligand, peptide, polymer, or other bioconjugation approaches to support delivery, targeting, or pharmacological performance.

For the fastest quote, share the therapeutic oligo type, target or mechanism, preferred chemistry or modification needs, intended application, and the current stage of your program.